| Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing J Zhang, J Fujimoto, J Zhang, DC Wedge, X Song, J Zhang, S Seth, ... Science 346 (6206), 256-259, 2014 | 916 | 2014 |
| Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial AT Shaw, L Gandhi, S Gadgeel, GJ Riely, J Cetnar, H West, DR Camidge, ... The lancet oncology 17 (2), 234-242, 2016 | 656 | 2016 |
| Osimertinib in pretreated T790M-positive advanced non-small-cell lung cancer: AURA study phase II extension component. JC Yang, MJ Ahn, DW Kim, SS Ramalingam, LV Sequist, S Wc, SW Kim, ... Journal of Clinical Oncology, 1288-1296, 2017 | 510 | 2017 |
| Phase III randomized trial of ipilimumab plus etoposide and platinum versus placebo plus etoposide and platinum in extensive-stage small-cell lung cancer M Reck, A Luft, A Szczesna, L Havel, SW Kim, W Akerley, MC Pietanza, ... Journal of Clinical Oncology 34 (31), 3740-3748, 2016 | 451 | 2016 |
| Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial SN Gettinger, LA Bazhenova, CJ Langer, R Salgia, KA Gold, R Rosell, ... The lancet oncology 17 (12), 1683-1696, 2016 | 309 | 2016 |
| Eat and exercise during radiotherapy or chemoradiotherapy for pharyngeal cancers: use it or lose it KA Hutcheson, MK Bhayani, BM Beadle, KA Gold, EH Shinn, SY Lai, ... JAMA otolaryngology–head & neck surgery 139 (11), 1127-1134, 2013 | 206 | 2013 |
| Targeted therapies in squamous cell carcinoma of the head and neck KA Gold, HY Lee, ES Kim Cancer: Interdisciplinary International Journal of the American Cancer …, 2009 | 152 | 2009 |
| Relationship between tumor size and survival in non–small-cell lung cancer (NSCLC): an analysis of the surveillance, epidemiology, and end results (SEER) registry J Zhang, KA Gold, HY Lin, SG Swisher, Y Xing, JJ Lee, ES Kim, ... Journal of Thoracic Oncology 10 (4), 682-690, 2015 | 130 | 2015 |
| Exploratory analysis of brigatinib activity in patients with anaplastic lymphoma kinase-positive non–small-cell lung cancer and brain metastases in two clinical trials DR Camidge, DW Kim, M Tiseo, CJ Langer, MJ Ahn, AT Shaw, RM Huber, ... Journal of Clinical Oncology 36 (26), 2693-2701, 2018 | 121 | 2018 |
| Selective antitumor activity of ibrutinib in EGFR-mutant non–small cell lung cancer cells W Gao, M Wang, L Wang, H Lu, S Wu, B Dai, Z Ou, L Zhang, JV Heymach, ... Journal of the National Cancer Institute 106 (9), dju204, 2014 | 106 | 2014 |
| Computed tomography RECIST assessment of histopathologic response and prediction of survival in patients with resectable non–small-cell lung cancer after neoadjuvant chemotherapy WN William Jr, A Pataer, N Kalhor, AM Correa, DC Rice, II Wistuba, ... Journal of Thoracic Oncology 8 (2), 222-228, 2013 | 104 | 2013 |
| Probing the building blocks of eumelanins using scanning electron microscopy JB Nofsinger, SE Forest, LM Eibest, KA Gold, JD Simon Pigment Cell Research 13 (3), 179-184, 2000 | 86 | 2000 |
| Erlotinib in the treatment of recurrent or metastatic cutaneous squamous cell carcinoma: a single‐arm phase 2 clinical trial KA Gold, MS Kies, WN William Jr, FM Johnson, JJ Lee, BS Glisson Cancer 124 (10), 2169-2173, 2018 | 84 | 2018 |
| Immune Modulation of Head and Neck Squamous Cell Carcinoma and the Tumor Microenvironment by Conventional TherapeuticsImmune Modulation in HNSCC by Conventional Therapies S Miyauchi, SS Kim, J Pang, KA Gold, JS Gutkind, JA Califano, LK Mell, ... Clinical Cancer Research 25 (14), 4211-4223, 2019 | 82 | 2019 |
| Safety and efficacy of brigatinib (AP26113) in advanced malignancies, including ALK+ non–small cell lung cancer (NSCLC). DR Camidge, L Bazhenova, R Salgia, CJ Langer, KA Gold, R Rosell, ... Journal of Clinical Oncology 33 (15_suppl), 8062-8062, 2015 | 80 | 2015 |
| Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: An open-label, multi-arm, non-randomised, multicentre, phase 2 trial AG Sacco, R Chen, FP Worden, DJL Wong, D Adkins, P Swiecicki, ... The Lancet Oncology 22 (6), 883-892, 2021 | 77 | 2021 |
| Relation between the level of lymph node metastasis and survival in locally advanced head and neck squamous cell carcinoma Y Xing, J Zhang, H Lin, KA Gold, EM Sturgis, AS Garden, JJ Lee, ... Cancer 122 (4), 534-545, 2016 | 77 | 2016 |
| Safety and efficacy of pembrolizumab with chemoradiotherapy in locally advanced head and neck squamous cell carcinoma: a phase IB study SF Powell, KA Gold, MM Gitau, CJ Sumey, MM Lohr, SC McGraw, ... Journal of Clinical Oncology 38 (21), 2427, 2020 | 71 | 2020 |
| The microRNA-200/Zeb1 axis regulates ECM-dependent β1-integrin/FAK signaling, cancer cell invasion and metastasis through CRKL C Ungewiss, ZH Rizvi, JD Roybal, DH Peng, KA Gold, DH Shin, ... Scientific reports 6 (1), 18652, 2016 | 68 | 2016 |
| Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor-Resistant, EGFR-Mutated Non-Small Cell Lung Cancer. PA Jänne, C Baik, WC Su, ML Johnson, H Hayashi, M Nishio, DW Kim, ... Cancer discovery 12 (1), 74-89, 2021 | 64 | 2021 |
